RG 002 - RinuaGene Biotechnology
Alternative Names: RG 002Latest Information Update: 21 Mar 2024
At a glance
- Originator RinuaGene Biotechnology
- Class Papillomavirus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Human papillomavirus infections
Most Recent Events
- 22 Feb 2024 Preclinical trials in Human papillomavirus infections in China (IM), prior to February 2024
- 22 Feb 2024 RinuaGene Biotechnology plans a phase I/II trial for Human papillomavirus infections (In adults) (IM, Injection), in March 2024 (NCT06273553)